Lexology December 9, 2024
Morgan Lewis & Bockius LLP

By Stephen Forster, Alexander Hastings and Howard Young (December 9, 2024, 6:52 PM EST)

Shortly after the new year, a Trump-Vance administration will control the White House, and the Republicans will hold a narrow majority in both the U.S. House of Representatives and U.S. Senate.

This control trifecta is likely to affect both legislative and regulatory processes and provide pathways for potential changes to the drug pricing and reimbursement landscapes.

While President-elect Donald Trump has yet to articulate priorities with respect to drug pricing and reimbursement, his reform efforts during his prior administration and the ongoing bipartisan focus on drug affordability suggest that drug pricing will continue to be under scrutiny.

Stephen Forster

We discuss herein key drug pricing programs...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicaid, Medicare, Pharma, Pharma / Biotech
Related Articles:
Congressional spending plan: What’s in it for healthcare, and what isn’t
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Another House bill aims to protect against hospital cyberattacks
A health care earthquake in Congress

Share This Article